While it did not affect the primary endpoint of major adverse cardiovascular events, targeted vitamin D supplementation was linked to reduced risk for recurrent heart attack, according to results of ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Medpage Today on MSN
Salmonella Paratyphi A Vaccine Protected Against Infection
An investigational live attenuated vaccine led to protection against Salmonella enterica serovar Paratyphi A infection, ...
Single-fraction SBRT did not significantly improve bone pain compared to conventional RT. Complete response rates were 37% with SBRT versus 25% with 3D conformal RT at 1 month and remained ...
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback